Sophiris Bio (SPHS) Narrows Q3 Loss

Sophiris Bio (NASDAQ: SPHS) reported Q3 EPS of ($0.22), versus ($0.49) reported last year.

Sophiris said, "At September 30, 2015, we had cash, cash equivalents and securities available-for-sale of $9.9 million and net working capital of $7.6 million. We expect that our cash, cash equivalents and securities available-for-sale as of September 30, 2015 will be sufficient to fund our operations through the end of April 2016 assuming that we do not initiate any additional clinical development of PRX302. We will need to obtain additional capital to fund a second Phase 3 clinical trial of PRX302 for the treatment of the symptoms of BPH and for any future clinical development of PRX302 for the treatment of localized prostate cancer beyond our ongoing Phase 2a proof of concept clinical trial."

For earnings history and earnings-related data on Sophiris Bio (SPHS) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Bit Digital (BTBT) Misses Q2 EPS by 27c
• Cantor Fitzgerald Reiterates Overweight Rating on Global Net Lease (GNL)